Automate Your Wheel Strategy on MRNA
With Tiblio's Option Bot, you can configure your own wheel strategy including MRNA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRNA
- Rev/Share 4.9566
- Book/Share 22.0663
- PB 2.279
- Debt/Equity 0.2215
- CurrentRatio 3.2934
- ROIC -0.297
- MktCap 19649994554.0
- FreeCF/Share -5.2398
- PFCF -9.5667
- PE -6.9857
- Debt/Assets 0.1553
- DivYield 0
- ROE -0.3015
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MRNA | Barclays | -- | Equal Weight | -- | $25 | Jan. 28, 2026 |
| Resumed | MRNA | UBS | -- | Neutral | -- | $34 | Jan. 7, 2026 |
| Initiation | MRNA | Jefferies | -- | Hold | -- | $30 | Dec. 12, 2025 |
| Initiation | MRNA | Citigroup | -- | Neutral | -- | $40 | March 13, 2025 |
| Downgrade | MRNA | Barclays | Overweight | Equal Weight | $111 | $45 | Feb. 18, 2025 |
| Downgrade | MRNA | Goldman | Buy | Neutral | $99 | $51 | Jan. 29, 2025 |
| Downgrade | MRNA | Argus | Buy | Hold | -- | -- | Dec. 18, 2024 |
| Resumed | MRNA | BofA Securities | -- | Underperform | -- | $41 | Dec. 10, 2024 |
| Initiation | MRNA | Bernstein | -- | Market Perform | -- | $55 | Oct. 17, 2024 |
| Downgrade | MRNA | Jefferies | Buy | Hold | $120 | $65 | Sept. 13, 2024 |
News
Moderna Stock: How Far Can The Flu Shot Fly?
Published: February 24, 2026 by: Forbes
Sentiment: Positive
Moderna (MRNA) – a developer of mRNA-focused therapeutics and vaccines – has recorded a 6-day winning streak, accumulating gains of 25% during this time. The company's market capitalization has increased by approximately $4.0 billion over the past 6 days and now sits at $20 billion.
Read More
BioNTech sues Moderna for patent infringement over COVID-19 shots
Published: February 19, 2026 by: Reuters
Sentiment: Negative
Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing shot Comirnaty.
Read More
Moderna Stock Jumps After FDA Reverses Course on Flu Shot
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Positive
MRNA stock rises 6% as the FDA agrees to review its flu vaccine filing after a surprise reversal, with a decision expected by Aug. 5, 2026.
Read More
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars
Published: February 18, 2026 by: Benzinga
Sentiment: Positive
The stock's movement comes after the U.S. Food and Drug Administration (FDA) notified Moderna that its biologics license application for mRNA-1010 will proceed to review, adding pressure as broader markets experienced mixed trading.
Read More
Moderna's investigational flu vaccine moves forward in FDA review
Published: February 18, 2026 by: Proactive Investors
Sentiment: Positive
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) announced that the US Food and Drug Administration (FDA) will initiate review of its investigational seasonal influenza vaccine, mRNA-1010, following a Type A meeting between the company and the agency. Shares of Moderna added 6.5% at about $47 on the update.
Read More
Moderna Shares Rally 6% After FDA Reverses Decision Not To Review Flu Vaccine
Published: February 18, 2026 by: Forbes
Sentiment: Positive
The FDA's “refuse-to-file” letter sent to reject Moderna's application is a rarity: A 2021 study found that 4% of the nearly 2,500 applications submitted to the agency receive such letters, many of which cited drug efficacy, safety and quality.
Read More
Moderna got the FDA to change its mind and review its flu vaccine after some concessions
Published: February 18, 2026 by: Market Watch
Sentiment: Positive
Moderna's stock was surging after the FDA said it would review the biotech's flu-vaccine candidate, a week after it had refused to do so.
Read More
Moderna Stock Pops as FDA Application Moves Forward
Published: February 18, 2026 by: Schaeffers Research
Sentiment: Positive
Pharma giant Moderna Inc (NASDAQ:MRNA) is enjoying a boost today, after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine application for review.
Read More
FDA reverses decision not to review Moderna's new flu vaccine
Published: February 18, 2026 by: New York Post
Sentiment: Neutral
The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.
Read More
Moderna Says FDA Will Review Its Flu Vaccine. The Stock Is Rising.
Published: February 18, 2026 by: Barrons
Sentiment: Positive
The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month.
Read More
The FDA reversed course and agreed to begin a review of Moderna's seasonal flu shot
Published: February 18, 2026 by: WSJ
Sentiment: Positive
The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season.
Read More
Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders
Published: February 16, 2026 by: Zacks Investment Research
Sentiment: Positive
MRNA shares jumped 5.3% as investors rotated into large-cap biotech, betting on its expanding pipeline in volatile trade.
Read More
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Published: February 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. (MRNA) Q4 2025 Earnings Call Transcript
Read More
Moderna Q4 Loss Narrower-Than-Expected, Sales Beat Estimates
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and reaffirming 2026 outlook.
Read More
CPI Increased in Line With Expectations
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Positive
As far as economic reports go, the good news just keeps on coming. Seemingly running on a separate track from investor fears about AI's future role in the economy, today's latest inflation read came in as well as anyone has the right to expect.
Read More
Moderna shares pop on strong guidance, smaller-than-expected loss
Published: February 13, 2026 by: Proactive Investors
Sentiment: Positive
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported fourth quarter 2025 results that exceeded Wall Street expectations, sending its shares up about 11% on Friday. The company posted a net loss of $2.11 per share on revenue of $678 million, compared with analysts' consensus of a $2.60 loss on revenue near $660 million.
Read More
Moderna (MRNA) Reports Q4 Loss, Beats Revenue Estimates
Published: February 13, 2026 by: Zacks Investment Research
Sentiment: Neutral
Moderna (MRNA) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.6. This compares to a loss of $2.5 per share a year ago.
Read More
Moderna Pops On Fourth-Quarter Report, But Can It Overcome Recent FDA Setbacks?
Published: February 13, 2026 by: Investors Business Daily
Sentiment: Positive
Moderna stock popped Friday after the company reported better-than-expected fourth-quarter sales and reiterated its 2026 outlook.
Read More
Moderna Stock Sports Technical Support Ahead Of Earnings
Published: February 12, 2026 by: Forbes
Sentiment: Negative
Pharma stock Moderna (MRNA) is experiencing a sharp pullback from its Jan. 22, 52-week high of $55.20. Last seen down 3.5% at $39.08, the shares are headed for their third-straight weekly loss.
Read More
FDA blindsides Moderna with refusal to review flu vaccine application: ‘We're pretty confused'
Published: February 11, 2026 by: New York Post
Sentiment: Neutral
The new shot was not compared to “the best-available standard of care in the United States at the time of the study,” an FDA official told Moderna.
Read More
Moderna's investigational flu vaccine denied FDA review, shares drop
Published: February 11, 2026 by: Proactive Investors
Sentiment: Negative
Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares fell almost 6% after the drugmaker announced that the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has issued a Refusal-to-File (RTF) letter for the company's biologics license application for its investigational seasonal influenza vaccine, mRNA-1010. According to the company, the FDA cited the choice of a licensed standard-dose influenza vaccine as the comparator in Moderna's Phase 3 trial as the reason for the refusal.
Read More
MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Negative
Moderna shares sink 10% after FDA issues Refusal-to-File letter for its mRNA-1010 flu vaccine, citing trial design concerns despite no safety flags.
Read More
Moderna's work developing seasonal vaccines is ‘risky' under current FDA, analyst says
Published: February 11, 2026 by: Market Watch
Sentiment: Negative
The biotech company said the FDA won't review its flu vaccine, in the latest hit to mRNA development.
Read More
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.
Read More
Moderna (MRNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Here is What to Know Beyond Why Moderna, Inc. (MRNA) is a Trending Stock
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Positive
Moderna (MRNA) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.
Published: February 04, 2026 by: GlobeNewsWire
Sentiment: Neutral
MIAMI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long MRNA ETF (MRNX) , expanding its lineup of single-stock leveraged ETFs designed for active traders seeking amplified exposure to innovative companies at the forefront of biotechnology and life sciences. MRNX is designed for traders seeking magnified, short-term bullish exposure to Moderna, Inc. (NASDAQ: MRNA), a biotechnology company known for its messenger RNA (mRNA)–based medicines and vaccine development platform.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Moderna (MRNA) Stock Falls Amid Market Uptick: What Investors Need to Know
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Negative
Moderna (MRNA) concluded the recent trading session at $42.55, signifying a -3.45% move from its prior day's close.
Read More
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Published: January 30, 2026 by: Seeking Alpha
Sentiment: Neutral
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi and Pfizer, targeting ~$500m annual revenues by 2030, with a forward P/S of ~3x and P/E of ~7.5x. MRNA's growth depends on COVID/flu combo vaccine, intismeran cancer program, and RSV vaccine, but faces higher risk due to elevated spending and lack of major partners.
Read More
About Moderna, Inc. (MRNA)
- IPO Date 2018-12-07
- Website https://www.modernatx.com
- Industry Biotechnology
- CEO Stéphane Bancel
- Employees 5800